EuroBiotech—More articles of note

Newspapers

> Shares in GeNeuro fell 65% after its multiple sclerosis candidate failed to cut the number of cerebral Gad-enhancing lesions in a phase 2b trial. The study of the Servier-partnered antibody will continue up to the 12-month readout. But the failure of GNbAC1 to outperform placebo in terms of reducing lesions or relapses has dampened expectations. Statement (PDF)

> AbbVie pulled a phase 1 trial of ABBV-553 prior to enrollment on safety grounds. The action raises doubts about the future of the RORγT inverse agonist, which emerged from AbbVie’s work with French biotech Inventiva. Protocol

> Seattle Genetics exercised its option to co-develop tisotumab vedotin with Genmab. The Danish drugmaker is currently testing the antibody-drug conjugate in a phase 1/2 trial in patients with solid tumors. Seattle Genetics and Genmab will split all future costs and profits. Statement

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Amcure received a €1.8 million grant to support the development of CD44v6 inhibitor AMC303. The German biotech is currently testing the drug in patients with metastatic epithelial tumors in a phase 1/2 trial. Release

> The FDA restated its concerns about the safety and efficacy of Kamada’s inhaled alpha-1 antitrypsin candidate. The Israeli biotech wants to run a phase 3 trial of the formulation but has yet to persuade the FDA to authorize it to proceed with the study. Statement

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.